It would seem that Rahway made a very savvy bet, in spending about $11.5 billion to acquire Acceleron in September of 2021.
That company's lead candidate, sotatercept -- originally for PAH, looks now to sail through -- with a new series of FDA green lights. [Here's just one of several, we've offered in the past, on the candidate -- now approved, as respiratory therapy.]
This is why Merck saw a slight increase in price, on the NYSE today. Here's some very cogent analysis, from FiercePharma, so I'll just turn you over -- to them:
. . .Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition.
In the phase 3 ZENITH study, Merck’s activin signaling inhibitor Winrevair, also known as sotatercept, met its primary endpoint of time to first morbidity or mortality event — which included all-cause death, lung transplantation, or hospitalization for at least 24 hours linked to disease worsening — and helped reduce the risk of morbidity or mortality events versus placebo in adults with pulmonary arterial hypertension (PAH) in functional class III or IV.
Patients in the trial’s study drug and control arms both received background PAH therapy, too. . . .
And, we will be closing shop for the week, likely around noon tomorrow -- grin. Unless something truly interesting breaks, we may not return here -- until next Monday. Be excellent to one another, and be thankful for all that is still wonderful in our world! We are all. . . so fortunate -- to be alive, at a time when medicine is pushing back the possibility of early-deaths, from avoidable causes.
नमस्ते
No comments:
Post a Comment